tbuckley/cabot-search huggingface dataset:
Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials
Authors: Pralay Mukhopadhyay, Jiabu Ye, Keaven M. Anderson, Satrajit Roychoudhury, Eric H. Rubin, Susan Halabi, Richard J. Chappell
Journal: JAMA Oncology (2022)

The log-rank test is considered the criterion standard for comparing 2 survival curves in pivotal registrational trials. However, with novel immunotherapies that often violate the proportional hazards assumptions over time, log-rank can lose power and may fail to detect treatment benefit. The MaxCombo test, a combination of weighted log-rank tests, retains power under different types of nonproportional hazards. The difference in restricted mean survival time (dRMST) test is frequently proposed as an alternative to the log-rank under nonproportional hazard scenarios.To compare the log-rank with the MaxCombo and dRMST in immuno-oncology trials to evaluate their performance in practice.Comprehensive literature review using Google Scholar, PubMed, and other sources for randomized clinical trials published in peer-reviewed journals or presented at major clinical conferences before December 2019 assessing efficacy of anti-programmed cell death protein-1 or anti-programmed death/ligand 1 monoclonal antibodies.Pivotal studies with overall survival or progression-free survival as the primary or key secondary end point with a planned statistical comparison in the protocol. Sixty-three studies on anti-programmed cell death protein-1 or anti-programmed death/ligand 1 monoclonal antibodies used as monotherapy or in combination with other agents in 35 902 patients across multiple solid tumor types were identified.Statistical comparisons (n = 150) were made between the 3 tests using the analysis populations as defined in the original protocol of each trial.Nominal significance based on a 2-sided .05-level test was used to evaluate concordance. Case studies featuring different types of nonproportional hazards were used to discuss more robust ways of characterizing treatment benefit instead of sole reliance on hazard ratios.In this systematic review and meta-analysis of 63 studies including 35 902 patients, between the log-rank and MaxCombo, 135 of 150 comparisons (90%) were concordant; MaxCombo achieved nominal significance in 15 of 15 discordant cases, while log-rank did not. Several cases appeared to have clinically meaningful benefits that would not have been detected using log-rank. Between the log-rank and dRMST tests, 137 of 150 comparisons (91%) were concordant; log-rank was nominally significant in 5 of 13 cases, while dRMST was significant in 8 of 13. Among all 3 tests, 127 comparisons (85%) were concordant.The findings of this review show that MaxCombo may provide a pragmatic alternative to log-rank when departure from proportional hazards is anticipated. Both tests resulted in the same statistical decision in most comparisons. Discordant studies had modest to meaningful improvements in treatment effect. The dRMST test provided no added sensitivity for detecting treatment differences over log-rank.
Asymptomatic Cutaneous Plaques on the Scalp and Face in an Older Adult Woman
Authors: Xuemei Lan, Hao Chen, Yiqun Jiang
Journal: JAMA Oncology (2022)

A 79-year-old female patient presented with a 2-year history of asymptomatic erythematous-infiltrated patches and plaques on the right side of her scalp and face, which gradually enlarged and coalesced into large plaques and nodules. What is your diagnosis?
Lipid-Associated Macrophages Are Induced by Cancer-Associated Fibroblasts and Mediate Immune Suppression in Breast Cancer
Authors: Eleonora Timperi, Paul Gueguen, Martina Molgora, Ilaria Magagna, Yann Kieffer, Silvia Lopez-Lastra, Philemon Sirven, Laura G. Baudrin, Sylvain Baulande, André Nicolas, Gabriel Champenois, Didier Meseure, Anne Vincent-Salomon, Anne Tardivon, Enora Laas, Vassili Soumelis, Marco Colonna, Fatima Mechta-Grigoriou, Sebastian Amigorena, Emanuela Romano
Journal: Cancer Research (2022)

Abstract Tumor-associated macrophages (TAM) play a detrimental role in triple-negative breast cancer (TNBC). In-depth analysis of TAM characteristics and interactions with stromal cells, such as cancer-associated fibroblast (CAF), could provide important biological and therapeutic insights. Here we identify at the single-cell level a monocyte-derived STAB1+TREM2high lipid-associated macrophage (LAM) subpopulation with immune suppressive capacities that is expanded in patients resistant to immune checkpoint blockade (ICB). Genetic depletion of this LAM subset in mice suppressed TNBC tumor growth. Flow cytometry and bulk RNA sequencing data demonstrated that coculture with TNBC-derived CAFs led to reprogramming of blood monocytes towards immune suppressive STAB1+TREM2high LAMs, which inhibit T-cell activation and proliferation. Cell-to-cell interaction modeling and assays in vitro demonstrated the role of the inflammatory CXCL12–CXCR4 axis in CAF–myeloid cell cross-talk and recruitment of monocytes in tumor sites. Altogether, these data suggest an inflammation model whereby monocytes recruited to the tumor via the CAF-driven CXCL12–CXCR4 axis acquire protumorigenic LAM capacities to support an immunosuppressive microenvironment. Significance: This work identifies a novel lipid–associated macrophage subpopulation with immune suppressive functions, offering new leads for therapeutic interventions in triple-negative breast cancer.
Cutaneous manifestations of lymphoid-variant hypereosinophilic syndrome
Authors: Claire Laurent, Guillaume Lefèvre, Jean-Emmanuel Kahn, Delphine Staumont-Salle, Renaud Felten, Marie Puget, Thomas Moulinet, Irène Machelart, David Launay, Estelle Charvet, Jean David Bouaziz, Marie Jachiet, Alexandra Espitia, Alfred Mahr, Christian Le Clech, Marion Malphettes, Cécile Morice, Samia Mourah, Hélène Moins-Teisserenc, François Lifermann, Karine Soulier-Guérin, Alban Villate, Chloé Baillou, Aurélie Grados, Ailsa Robbins, Noemie Abisror, Martine Bagot, David Boutboul, Kewin Panel, Marie-Dominique Vignon-Pennamen, Jacqueline Rivet, Maxime Battistella, Matthieu Groh, Adèle de Masson
Journal: British Journal of Dermatology (2022)

Abstract
ELF4 is a critical component of a miRNA-transcription factor network and is a bridge regulator of glioblastoma receptor signaling and lipid dynamics
Authors: Adam Kosti, Jennifer Chiou, Gabriela D A Guardia, Xiufen Lei, Henriette Balinda, Tesha Landry, Xiyuan Lu, Mei Qiao, Andrea Gilbert, Andrew Brenner, Pedro A F Galante, Stefano Tiziani, Luiz O F Penalva
Journal: Neuro-Oncology (2022)

Abstract Background The loss of neurogenic tumor suppressor microRNAs miR-124, miR-128, and miR-137 is associated with glioblastoma’s undifferentiated state. Most of their impact comes via the repression of a network of oncogenic transcription factors. We conducted a high-throughput functional siRNA screen in glioblastoma cells and identify E74 like ETS transcription factor 4 (ELF4) as the leading contributor to oncogenic phenotypes. Methods In vitro and in vivo assays were used to assess ELF4 impact on cancer phenotypes. We characterized ELF4’s mechanism of action via genomic and lipidomic analyses. A MAPK reporter assay verified ELF4’s impact on MAPK signaling, and qRT-PCR and western blotting were used to corroborate ELF4 regulatory role on most relevant target genes. Results ELF4 knockdown resulted in significant proliferation delay and apoptosis in GBM cells and long-term growth delay and morphological changes in glioma stem cells (GSCs). Transcriptomic analyses revealed that ELF4 controls two interlinked pathways: 1) Receptor tyrosine kinase signaling and 2) Lipid dynamics. ELF4 modulation directly affected receptor tyrosine kinase (RTK) signaling, as mitogen-activated protein kinase (MAPK) activity was dependent upon ELF4 levels. Furthermore, shotgun lipidomics revealed that ELF4 depletion disrupted several phospholipid classes, highlighting ELF4’s importance in lipid homeostasis. Conclusions We found that ELF4 is critical for the GBM cell identity by controlling genes of two dependent pathways: RTK signaling (SRC, PTK2B, and TNK2) and lipid dynamics (LRP1, APOE, ABCA7, PLA2G6, and PITPNM2). Our data suggest that targeting these two pathways simultaneously may be therapeutically beneficial to GBM patients.
Insights into male androgenetic alopecia using comparative transcriptome profiling: hypoxia-inducible factor-1 and Wnt/β-catenin signalling pathways
Authors: Qingmei Liu, Yulong Tang, Yan Huang, Ji’an Wang, Kai Yang, Yuting Zhang, Weilin Pu, Jing Liu, Xiangguang Shi, Yanyun Ma, Chunya Ni, Yue Zhang, Yifei Zhu, Haiyang Li, Jiucun Wang, Jinran Lin, Wenyu Wu
Journal: British Journal of Dermatology (2022)

The key pathophysiological changes in androgenetic alopecia (AGA) are limited to hair follicles (HFs) in frontal and vertex regions, sparing the occipital region.To identify biological differences among HF subpopulations.Paired vertex and occipital HFs from 10 male donors with AGA were collected for RNA sequencing assay. Furthermore, HF and cell experiments were conducted on the identified key genes to reveal their roles in AGA.Transcriptome profiles revealed that 506 mRNAs, 55 microRNAs and 127 long noncoding RNAs were differentially expressed in the AGA vertex HFs. Pathway analysis of mRNAs and microRNAs revealed involvement of the hypoxia-inducible factor (HIF)-1, Wnt/β-catenin, and focal adhesion pathways. Differential expression of HIF-1 prolyl hydroxylase enzymes (EGLN1, EGLN3) and Wnt/β-catenin pathway inhibitors (SERPINF1, SFRP2) was experimentally validated. In vitro studies revealed that reduction of EGLN1, EGLN3, SERPINF1 and SFRP2 stimulated proliferation of dermal papilla cells. Ex vivo HF studies showed that downregulation of EGLN1, EGLN3 and SERPINF1 promoted HF growth, postponed HF catagen transition, and prolonged the anagen stage, suggesting that these genes may be potentially utilized as therapeutic targets for AGA.We characterized key transcriptome changes in male AGA HFs, and found that HIF-1 pathway-related genes (EGLN1, EGLN3) and Wnt pathway inhibitors (SERPINF1, SFRP2) may play important roles in AGA. What is already known about this topic? Multiple differentially expressed genes and signalling pathways have been found between hair follicles (HFs) in the balding area (frontal and vertex regions) and nonbalding area (occipital region) of individuals with androgenetic alopecia (AGA). A whole-transcriptome atlas of the vertex and occipital region is lacking. What does this study add? We identified a number of differentially expressed genes and pathways between balding vertex and nonbalding occipital AGA HFs by using whole-transcriptome analyses. We identified pathways not previously reported in AGA, such as the hypoxia-inducible factor (HIF)-1 signalling pathway. We verified that HIF-1 pathway-related genes (EGLN1, EGLN3) and Wnt pathway inhibitors (PEDF, SFRP2) played important roles in dermal papilla cell activity, hair growth and the hair cycle. What is the translational message? The EGLN1, EGLN3, SERPINF1 and SFRP2 genes may be potentially utilized as therapeutic targets for AGA.
Uncovering Signals of Positive Selection in Peruvian Populations from Three Ecological Regions
Authors: Rocio Caro-Consuegra, Maria A Nieves-Colón, Erin Rawls, Verónica Rubin-de-Celis, Beatriz Lizárraga, Tatiana Vidaurre, Karla Sandoval, Laura Fejerman, Anne C Stone, Andrés Moreno-Estrada, Elena Bosch
Journal: Molecular Biology and Evolution (2022)

Peru hosts extremely diverse ecosystems which can be broadly classified into the following three major ecoregions: the Pacific desert coast, the Andean highlands, and the Amazon rainforest. Since its initial peopling approximately 12,000 years ago, the populations inhabiting such ecoregions might have differentially adapted to their contrasting environmental pressures. Previous studies have described several candidate genes underlying adaptation to hypobaric hypoxia among Andean highlanders. However, the adaptive genetic diversity of coastal and rainforest populations has been less studied. Here, we gathered genome-wide single-nucleotide polymorphism-array data from 286 Peruvians living across the three ecoregions and analyzed signals of recent positive selection through population differentiation and haplotype-based selection scans. Among highland populations, we identify candidate genes related to cardiovascular function (TLL1, DUSP27, TBX5, PLXNA4, SGCD), to the Hypoxia-Inducible Factor pathway (TGFA, APIP), to skin pigmentation (MITF), as well as to glucose (GLIS3) and glycogen metabolism (PPP1R3C, GANC). In contrast, most signatures of adaptation in coastal and rainforest populations comprise candidate genes related to the immune system (including SIGLEC8, TRIM21, CD44, and ICAM1 in the coast; CBLB and PRDM1 in the rainforest; and BRD2, HLA-DOA, HLA-DPA1 regions in both), possibly as a result of strong pathogen-driven selection. This study identifies candidate genes related to human adaptation to the diverse environments of South America.
Assessment of formal tobacco treatment and smoking cessation in dual users of cigarettes and e-cigarettes
Authors: Brendan T Heiden, Timothy B Baker, Nina Smock, Giang Pham, Jingling Chen, Laura J Bierut, Li-Shiun Chen
Journal: Thorax (2022)

Background The utility of electronic cigarettes (‘e-cigarettes’) as a smoking cessation adjunct remains unclear. Similarly, it is unclear if formal tobacco treatment (pharmacotherapy and/or behavioural support) augments smoking cessation in individuals who use both cigarettes and e-cigarettes. Methods We performed a longitudinal cohort study of adult outpatients evaluated in our tertiary care medical centre (6/2018–6/2020). E-cigarette use, smoking status and formal tobacco treatment (deterrent pharmacotherapy and/or behavioural support) were assessed in 6-month blocks (eg, cohort 1 (C1)=6/2018–12/2018, C2=1/2019–6/2019 and so on) using our electronic health record. We assessed the relationship between e-cigarette use (either with or without formal tobacco treatment) and point prevalence of smoking cessation at 6 and 12 months. Results 111 823 unique patients were included in the study. The prevalence of dual use of cigarettes and e-cigarettes increased significantly over the study period (C1=0.8%; C2=1.1%; C3=1.8%; C4=2.3%; p&lt;0.001). The prevalence of smoking cessation at 12 months was higher among e-cigarette users (20.8%) compared with non-users (16.8%) (risk difference, 4.0% (95% CI 2.5% to 5.5%); adjusted relative risk (aRR) 1.354, 95% CI 1.252 to 1.464, p&lt;0.0001). Further, among dual users of cigarettes and e-cigarettes, the prevalence of smoking cessation at 12 months was higher among individuals who received tobacco treatment (29.1%) compared with individuals who did not receive tobacco treatment (19.6%) (risk difference, 9.5% (95% CI, 4.6% to 14.4%); aRR 1.238, 95% CI 1.071 to 1.432, p=0.004). Interpretation These results suggest that dual users of cigarettes and e-cigarettes benefit from formal tobacco treatment. Clinicians should consider offering formal tobacco treatment to such patients, though future trials are needed.
Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options
Authors: Jae Young So, Joyce Ohm, Stan Lipkowitz, Li Yang
Journal: Pharmacology & Therapeutics (2022)

Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by extensive intra-tumoral heterogeneity, and frequently develops resistance to therapies. Tumor heterogeneity and lack of biomarkers are thought to be some of the most difficult challenges driving therapeutic resistance and relapse. This review will summarize current therapy for TNBC, studies in treatment resistance and relapse, including data from recent single cell sequencing. We will discuss changes in both the transcriptome and epigenome of TNBC, and we will review mechanisms regulating the immune microenvironment. Lastly, we will provide new perspective in patient stratification, and treatment options targeting transcriptome dysregulation and the immune microenvironment of TNBC patients.
MO35-1 The feasibility and utility of a mobile app in supporting Vietnamese children with cancer
Authors: Quy Pham Nguyen, Chau Duc Nguyen Huu, Nam Ha Xuan, Thao Ngan Nguyen Thi, Hong Tram Nguyen Thi, Thanh Thu Nguyen Thi, Hong Duyen Nguyen, Khoi Quan Nguyen, Minh Trang Nguyen Ho, Hiep Pham Nhu, Thanh Xuan Nguyen, Kiem Hao Tran, Van Ha Chau, Diem Chi Nguyen Thi, Huu Son Nguyen, Tomohiro Kondo, Shigemi Matsumoto
Journal: Annals of Oncology (2022)
P74-4 FOLFOXIRI+a is an ideal regimen for conversion in the treatment of advanced/recurrent colorectal cancer
Authors: Kazuma Kobayashi, Takuro Fujita, Yusuke Inoue, Satomi Okada, Toshiyuki Adachi, Sayaka Kuba, Michi Morita, Taiichiro Kosaka, Takayuki Tanaka, Shinichiro Kobayashi, Yasuhiro Maruya, Akihiko Soyama, Tomohiko Adachi, Minoru Fukuda, Takuya Honda, Shinichiro Ito, Masaaki Hidaka, Kengo Kanetaka, Susumu Eguchi
Journal: Annals of Oncology (2022)
MO27-5 Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma: a retrospective study
Authors: Hiroyuki Kodama, Shigenori Kadowaki, Akinobu Nakata, Ryosuke Kumanishi, Taiko Nakazawa, Takatsugu Ogata, Yuki Matsubara, Kazunori Honda, Toshiki Masuishi, Yukiya Narita, Hiroya Taniguchi, Masashi Ando, Nobuhiro Hanai, Kei Muro
Journal: Annals of Oncology (2022)
MO17-1 Clinical practice of comprehensive genomic profiling in gynecologic malignancies at National Cancer Center Hospital
Authors: Yohei Chiba, Kazuki Sudo, Motoko Arakaki, Ayumi Saito, Momoko Tokura, Syu Yazaki, Chiharu Mizoguchi, Hitomi Okuma, Syosuke Kita, Kasumi Yamamoto, Yuki Kojima, Tadaaki Nishikawa, Emi Noguchi, Tatsunori Shimoi, Kan Yonemori
Journal: Annals of Oncology (2022)
O14-4 Association of financial toxicity with quality-of-life in patients with gynecologic cancer
Authors: Kazunori Honda, Hirofumi Tsubouchi, Masahiko Mori, Shiro Suzuki, Kohshiro Nakao, Anri Azuma, Shoji Nagao, Takashi Shibutani, Takahiro Koyanagi, Izumi Kohara, Shuko Tamaki, Midori Yabuki, Lida Teng, Yusuke Kajimoto, Ataru Igarashi
Journal: Annals of Oncology (2022)
MO22-1 Outcomes and Risk Factors of Patients with COVID-19 and Cancer (ONCORONA): A Sub-study of the Philippine CORONA study
Authors: Ramon Jr B. Larrazabal, Adrian I. Espiritu, Marie Charmaine C. Sy, Veeda Michelle M. Anlacan, Roland Dominic G. Jamora
Journal: Annals of Oncology (2022)
P11-2 A case of combined hepatocellular-cholangiocarcinoma successfully treated with atezolizumab plus bevacizumab
Authors: Takafumi Kitazono, Shohei Ueno, Tomomi Koike, Yudai Shinohara, Daisuke Yamada, Junichi Motoshita, Hozumi Shimokawa, Yasunori Ichiki
Journal: Annals of Oncology (2022)
P31-5 Situation of cervical cancer in Mittaphab Hospital, Vientiane Capital city, Lao PDR in 2017-2020, a retrospective study
Authors: Viengsavanh Vieng Khammounheuang, Douangprachanh Tik Sathathone, Sengthong Teed Mounphoumi, Vanida Kood Khammounheuang
Journal: Annals of Oncology (2022)
O5-2 AMEERA-2: Phase 1 study of oral SERD amcenestrant (SAR439859) in Japanese women with ER+/HER2- advanced breast cancer
Authors: Haruru Kotani, Kenji Tamura, Toru Mukohara, Kan Yonemori, Yumiko Kawabata, Xavier Nicolas, Tomoyuki Tanaka, Hiroji Iwata
Journal: Annals of Oncology (2022)
MO6-1 Real-world treatment outcomes of metastatic pancreatic cancer in Japan: Tokushukai REAl-world Data project 03 (TREAD 03)
Authors: Rai Shimoyama, Yoshinori Imamura, Kiyoaki Uryu, Takahiro Mase, Yoshiaki Fujimura, Maki Hayashi, Megu Ohtaki, Keiko Otani, Nobuaki Shinozaki, Hironobu Minami
Journal: Annals of Oncology (2022)
P5-8 Current status and issues of cancer genome profiling tests for insurance at our hospital
Authors: Hidenori Kido, Shimada Naoko, Serizawa Nobuko, Gyouda Yu, Takasaki Yusuke, Fujino Kazunari, Nasu Motomi, Suzuki Mario, Shinichi Ooba, Sai Hyonmi, Junya Fujimura, Nagata Masayoshi, Shinano Hiromi, Tanaka Chemi, Hayashi Takuo, Mine Yuichirou, Eguchi Masataka, Arai Masami, Kato Shunsuke
Journal: Annals of Oncology (2022)
O2-6 Salvage local therapy for the progressive lesion after nivolumab in the patients with R/M SCCHN
Authors: Masanobu Sato, Tomohiro Enokida, Akihisa Wada, Susumu Okano, Hideki Tanaka, Takao Fujisawa, Yuri Ueda, Atsushi Motegi, Takeshi Shinozaki, Wataru Okano, Toshifumi Tomioka, Yohei Morishita, Naohiro Takeshita, Nobukazu Tanaka, Sadamoto Zenda, Kazuto Matsuura, Tetsuo Akimoto, Ryuichi Hayashi, Makoto Tahara
Journal: Annals of Oncology (2022)
O7-2 FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type mCRC: the subgroup-analysis of DEEPER trial (JACCRO CC-13)
Authors: Taichi Yabuno, Akihito Tsuji, Takuya Tokunaga, Satoshi Yuki, Toshihiro Kudo, Naoki Mashita, Koji Ando, Nobumichi Takeuchi, Tomomi Kashiwada, Masato Kataoka, Mitsugu Kochi, Tamotsu Sagawa, Masahito Kotaka, Yutaro Kubota, Yu Sunakawa, Takashi Sekikawa, Masato Nakamura, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii
Journal: Annals of Oncology (2022)
Doxorubicin-conjugated siRNA lipid nanoparticles for combination cancer therapy
Authors: Kamila Butowska, Xuexiang Han, Ningqiang Gong, Rakan El-Mayta, Rebecca M. Haley, Lulu Xue, Wenqun Zhong, Wei Guo, Karin Wang, Michael J. Mitchell
Journal: Acta Pharmaceutica Sinica B (2022)

Evasion of apoptosis is a hallmark of cancer, attributed in part to overexpression of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2). In a variety of cancer types, including lymphoma, Bcl-2 is overexpressed. Therapeutic targeting of Bcl-2 has demonstrated efficacy in the clinic and is the subject of extensive clinical testing in combination with chemotherapy. Therefore, the development of co-delivery systems for Bcl-2 targeting agents, such as small interfering RNA (siRNA), and chemotherapeutics, such as doxorubicin (DOX), holds promise for enabling combination cancer therapies. Lipid nanoparticles (LNPs) are a clinically advanced nucleic acid delivery system with a compact structure suitable for siRNA encapsulation and delivery. Inspired by ongoing clinical trials of albumin-hitchhiking doxorubicin prodrugs, here we developed a DOX-siRNA co-delivery strategy via conjugation of doxorubicin to the surface of siRNA-loaded LNPs. Our optimized LNPs enabled potent knockdown of Bcl-2 and efficient delivery of DOX into the nucleus of Burkitts' lymphoma (Raji) cells, leading to effective inhibition of tumor growth in a mouse model of lymphoma. Based on these results, our LNPs may provide a platform for the co-delivery of various nucleic acids and DOX for the development of new combination cancer therapies.
MO27-2 Prognostic impact of the number of metastatic lymph nodes after surgery in locally advanced hypopharyngeal cancer
Authors: Ari Nishimura, Yokota Tomoya, Hamauchi Satoshi, Onozawa Yusuke, Shirasu Hiromichi, Notsu Akifumi, Sato Fuyuki, Kawakami Takeshi, Ogawa Hirofumi, Onoe Tsuyoshi, Mukaigawa Takashi
Journal: Annals of Oncology (2022)
PS1-2 CLIP1-LTK: a novel target in non-small cell lung cancer
Authors: Hiroki Izumi, Shingo Matsumoto, Shunta Mori, Kumiko Hayashi, Kana Watanabe, Tatsuro Fukuhara, Yuji Shibata, Kiyotaka Yoh, Masahiro Morise, Ryo Toyozawa, Kenichi Chikamori, Shingo Miyamoto, Shuichi Asano, Masato Shingyoji, Mika Nakao, Koichi Azuma, Seiji Niho, Genichiro Ishii, S. Susumu Kobayashi, Koichi Goto
Journal: Annals of Oncology (2022)
O13-5 Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: Co-MET study
Authors: Ryo Toyozawa, Kaname Nosaki, Mototugu Shimokawa, Hidehito Horinouchi, Masahiro Morise, Kadoaki Ohashi, Haruyasu Murakami, Miyako Satouchi, Jun Sakakibara, Seiji Yano, Shingo Matsumoto, Koichi Goto, Takashi Seto, Kiyotaka Yoh
Journal: Annals of Oncology (2022)
PS1-5 IMpower010: results from Asian patients in a phase 3 study of adjuvant atezolizumab in resected stage IB-IIIA NSCLC
Authors: Hirotsugu Kenmotsu, Caicun Zhou, Nasser Altorki, Enriqueta Felip, Eric Vallieres, Shunichi Sugawara, Hiroshi Sakai, Haruhiro Saito, Min Tao, Koji Kawaguchi, Yunpeng Liu, Chong-Jen Yu, Qiong Wu, Huang Lin, Fan Wu, Elizabeth Bennett, Virginia Mcnally, Barbara Gitlitz, Heather Wakelee
Journal: Annals of Oncology (2022)